JAMA:PERC、YEARS以及年龄调整D二聚体阈值联合用于急诊肺栓塞诊断

2021-12-08 MedSci原创 MedSci原创

对于急诊科疑似肺栓塞患者,与PERC联合D二聚体指标诊断方案相比,添加YEARS规则未显著降低后续血栓事件风险

对于疑似肺栓塞(PE)患者的最佳诊断策略仍存在争议,传统的诊断根据D-二聚体测定和胸部影像学检查(CT肺血管造影术(CTPA)或肺通气/灌注[V/Q]扫描),但D-二聚体对PE的临床诊断特异性低,CTPA对PE的诊断率也仅在10%左右。研究人员开发了多种PE疑似患者排除方法,其中PERC规则(不满足以下全部条件可排除PE风险:年龄50岁以上、脉搏率≥100/min,动脉血氧饱和度<95%,单侧腿部肿胀、咯血、近期创伤或手术,既往PE或深静脉血栓史以及外源性雌激素的使用)或年龄调整的D-二聚体(50岁以上人群,D二聚体阈值为年龄×10 ng/mL)以及YEARS规则(3个标准:PE是最有可能的诊断、深静脉血栓形成临床症象和咯血,3条均无者,D-二聚体低于1000ng/mL可排除;满足1条以上者,D-二聚体低于500ng/mL可排除)。近日研究人员考察了PERC、YEARS规则以及年龄调整D-二聚体联合应用的临床价值。

本次研究在在法国和西班牙的18个急诊科(EDs)开展,为随机、交叉、非劣效性试验,总计1414名患者参与,存在至少1个PERC阳性指标,均不进行胸部成像,干预组包含726名患者,无YEARs阳性指标且D-二聚体水平低于1000 ng/mL或有1项YEARs阳性指标且D-二聚体水平低于年龄调整后阈值,则排除PE风险;对照组包含688名患者,若D-二聚体水平低于年龄调整后阈值则排除PE风险。研究的主要终点为3个月时静脉血栓栓塞(VTE),非劣效性边界为1.35%。次要终点包括胸部影像学异常、ED住院时间、住院时间、无指征抗凝治疗、全因死亡和3个月时全因再入院。

患者平均年龄55岁,女性占58%,1217名(86%)患者完成研究,其中100人急诊诊断为PE(7.1%)。3个月时,干预组1名患者出现VTE(0.15%),而对照组5名患者出现VTE(0.80%),调整后风险差异为-0.64%,满足非劣性终点。次要终点中,仅2项存在显著性差异,分别是胸部影像学异常(-8.7%)以及ED住院时间(-1.6小时),干预组表现出优势。

组间后续VTE风险差异不显著

研究认为,对于急诊科疑似肺栓塞患者,与PERC联合D二聚体指标诊断方案相比,添加YEARS规则未显著降低后续血栓事件风险

原始出处:

Yonathan Freund et al. Effect of a Diagnostic Strategy Using an Elevated and Age-Adjusted D-Dimer Threshold on Thromboembolic Events in Emergency Department Patients With Suspected Pulmonary Embolism A Randomized Clinical Trial. JAMA. December 7,2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1950395, encodeId=495419503952c, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Apr 17 03:53:51 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729226, encodeId=abe31e292265a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 19 16:53:51 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553632, encodeId=c6c61553632f3, content=<a href='/topic/show?id=839e9e33475' target=_blank style='color:#2F92EE;'>#阈值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97334, encryptionId=839e9e33475, topicName=阈值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f4f14387940, createdName=qjddjq, createdTime=Fri Dec 10 09:53:51 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078323, encodeId=d64110e832377, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c90a5343088, createdName=ms5000000833449414, createdTime=Thu Dec 09 08:41:35 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
    2022-04-17 hxj0117
  2. [GetPortalCommentsPageByObjectIdResponse(id=1950395, encodeId=495419503952c, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Apr 17 03:53:51 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729226, encodeId=abe31e292265a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 19 16:53:51 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553632, encodeId=c6c61553632f3, content=<a href='/topic/show?id=839e9e33475' target=_blank style='color:#2F92EE;'>#阈值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97334, encryptionId=839e9e33475, topicName=阈值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f4f14387940, createdName=qjddjq, createdTime=Fri Dec 10 09:53:51 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078323, encodeId=d64110e832377, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c90a5343088, createdName=ms5000000833449414, createdTime=Thu Dec 09 08:41:35 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
    2022-09-19 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1950395, encodeId=495419503952c, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Apr 17 03:53:51 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729226, encodeId=abe31e292265a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 19 16:53:51 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553632, encodeId=c6c61553632f3, content=<a href='/topic/show?id=839e9e33475' target=_blank style='color:#2F92EE;'>#阈值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97334, encryptionId=839e9e33475, topicName=阈值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f4f14387940, createdName=qjddjq, createdTime=Fri Dec 10 09:53:51 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078323, encodeId=d64110e832377, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c90a5343088, createdName=ms5000000833449414, createdTime=Thu Dec 09 08:41:35 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
    2021-12-10 qjddjq
  4. [GetPortalCommentsPageByObjectIdResponse(id=1950395, encodeId=495419503952c, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Sun Apr 17 03:53:51 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729226, encodeId=abe31e292265a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Sep 19 16:53:51 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553632, encodeId=c6c61553632f3, content=<a href='/topic/show?id=839e9e33475' target=_blank style='color:#2F92EE;'>#阈值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97334, encryptionId=839e9e33475, topicName=阈值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f4f14387940, createdName=qjddjq, createdTime=Fri Dec 10 09:53:51 CST 2021, time=2021-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078323, encodeId=d64110e832377, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c90a5343088, createdName=ms5000000833449414, createdTime=Thu Dec 09 08:41:35 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
    2021-12-09 ms5000000833449414

    学习了

    0

相关资讯

Radiology:对于COVID-19住院患者来说,肺栓塞并不仅仅是肺栓塞!

最新研究表明,SARS COV-2可与内皮细胞上的ACE-2受体结合,特别是在肾脏心脏、肺和肝脏内。内皮细胞损伤可导致血栓形成,这可以是一种防御机制,可将感染局限起来并防止进一步传的播。

Chest:心率可能是肺栓塞患者预后因素

肺栓塞患者入院心率与30天全因死亡率和肺栓塞相关死亡率呈正相关。

Front Pharmacol:microRNA在肺栓塞中的作用

肺栓塞(PE)是一种常见的病理状态,常发生于深静脉血栓形成患者。miRNA 作为 PE 生物标志物的功能,揭示了它们在静脉血栓形成中的机制、功能和靶点。

打麻将打出肺栓塞:?要人命的血栓要学会预防!

肺动脉一旦栓塞,肺部血流阻塞,吸入肺中的氧气不能顺利进入动脉血

JAHA:肺动脉压和左心室每搏量联合评估预测肺栓塞患者不良事件

这项研究首次证明了早期肺动脉收缩压/左心室每搏输出量在预测急性肺栓塞患者不良临床事件中的效用。肺动脉收缩压/左心室每搏输出量可能是高危肺栓塞心室不同步的替代指标,应进行预后评估。

长期服用避孕药----警惕肺栓塞

34岁的文小姐(化名)因咳血痰、胸痛、呼吸困难在当地医院就诊,肺CT示两下肺斑片状密度增高影,经抗感染治疗无好转,活动后呼吸困难加重,遂转诊到右医附院呼吸内科,经医生诊断,考虑可能存在肺栓塞,行肺动脉